SHANGHAI and SAN DIEGO, November 24, 2021 / PRNewswire / – Neurophth Biotechnology Ltd., a fully integrated genomic drug company focused on improving lives through the curative potential of gene therapies, today announced the recent appointment of Su Zhang, MBA, as Chief Financial Officer (CFO). Su will be responsible for the board of directors in corporate and operational finance as well as accounting and management functions.
Sir. Su Zhang has over 20 years of experience in corporate finance in the healthcare industry. He joins Neurophth after serving as CFO of Ascentage Pharma, leading the company on the Hong Kong Stock Exchange, as well as several subsequent refinancing and business development partnerships. Prior to joining Ascentage Pharma, he served as Director of Healthcare Equity Analyst at China Merchant Securities in Hong-Kong, China, as well as working at Standard Chartered Bank and BNP Paribas in London and Hong Kong for over 8 years.
Sir. Su Zhang holds a Master of Business Administration from HEC Paris School of Management, a Master of Science in accounting and finance from London School of Economics and Political Science and a bachelor’s degree in international business economics from Fudan University.
“We are fortunate to have an executive with financial acumen and Su’s pedigree who joins our leadership team as CFO,” said Bin Li, MD, Ph.D., Founder and President of Neurophth. “Su is a well-known and well-respected biotechnology leader with diverse experience in strategic investments, equity capital markets and partnerships. He has a proven track record as a business leader through rapid growth both in the national and international level. new role at Neurophth. “
“I am delighted to welcome Su as the new CFO,” said Alvin luk, Ph.D., MBA, CCRA, CEO of Neurophth. “Su has demonstrated his ability to successfully bring companies through IPO, financial growth and international expansion. His expertise in strategic financial leadership, strategic healthcare financing and strong investor relations, make him an ideal candidate for this role as we enter the next phase of growth for Neurophth. “
“Now is the perfect time to join Professor Li, Alvin and the Neurophth team,” Zhang added. “I am passionate about advancing science and working with companies to have a real impact on the lives of patients. Neurophth is emerging as an innovative and leading gene therapy company in the China. I look forward to joining the team and helping the company advance its vision of developing transformative therapies for unmet medical needs. “
The neuropath is from China first gene therapy company for ophthalmic diseases. With subsidiaries in China (Wuhan, Shanghai, and Suzhou) and the United States (San diego, california), Neurophth, a fully integrated company, strives to discover and develop genomic drugs for patients with genetic diseases around the world. Our validated AAV platform, published in Nature – Scientific reports, Ophthalmology, and EBioMedicine, has provided data from successful proof of concept trials initiated by researchers on 198 subjects with experimental gene therapies in the retina. Our most advanced experimental candidate NR082 (core project NFS-01), in development for the treatment of ND4Leber’s hereditary optic neuropathy (ND4-LHON), received Orphan Drug Designation (ODD) by the US FDA and its IND evaluating NR082 in an integrated phase 1/2/3 clinical trial was also approved by the Chinese NMPA in March 2021 with the first patient being dosed into June 2021. The pipeline also includes ND1-LHON mediated, autosomal dominant optic atrophy, optic neuroprotection (for example, glaucoma), vascular retinopathy (for example, diabetic retinopathy) and five other preclinical candidates. Neurophth initiated the large-scale in-house manufacturing process in single-use technologies to meet future business demand at the Suzhou facility. To learn more about us and our growing pipeline, visit www.neurophth.com.
SOURCE Neurophth Therapeutics, Inc.